LinkedIn YouTube Bluesky
Search
English / Français
Ethics Portal
LinkedIn YouTube Bluesky
Search
English / Français
Ethics Portal
  • Who We Are
    • About Us
    • Business Model
    • Our Strategy 2023-2025
    • Statutes, By-Laws & Policies
    • Governance & Team
    • Annual Reports
    • Careers & RFPs
  • What We Do
    • Licensing for Public Health
    • MRNA Technology Transfer Programme
    • Disease Areas
    • Focus areas
      • Biotherapeutics
      • Local and Regional Manufacturing
      • Pandemic Preparedness and Response
      • Upstream Access
      • Technology Transfer
    • Addressing Children's Needs
    • Patent Information Tools
      • MedsPaL
      • LAPaL
    • Long-Acting Therapeutics
  • Progress
    • Prioritisation
    • Agreements with Innovators
    • Access to Medicines Tracker
    • Contribution to Universal Health Coverage
    • Endorsements
    • Impact
  • News & Publications
    • News, Events & Press Releases
    • Messages from the Executive Director
    • MPP in the Media
    • MPP Publications
    • Related Publications
    • Newsletters & Updates
  • Partners
    • Partnering with MPP
    • Our Stories
      • Voices from Friends of MPP
      • Voices from the Frontline
      • I am part of the DTG story
    • Funders
    • How to Give or Get a Licence
  • Contact Us

Document

Click here to access the document

news & publications » Document

Statutes of the MPP

1 November 2019

Share page:
Facebook
Linkedin
Bluesky

Contact Us

Press and Media

About Us

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.

MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.

MPP Logo

Subscribe to our Newsletter

Subscribe to our Newsletter

Subscribe

* indicates required






The Medicines Patent Pool will use the information (email address) you provide on this form to be in touch with you and to provide updates.


You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at press@medicinespatentpool.org. We will treat your information with respect. For more information about our privacy practices, please visit our website. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp’s privacy practices here.


About Us
Licences
MedsPaL
Careers & RFPs
Privacy Policy
Contact

Founded & funded by

Unitaid Logo

Other funders